Nasdaq

Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

Treatment with fezolinetant resulted in statistically significant reductions in the frequency and severity of VMS and improvements in quality of life The study met the four coprimary efficacy ...
Yahoo Finance

Skylight Health Announces Expansion of ClinEdge Partnership and Award for First Colorado Study

The expanded partnership with ClinEdge will bring industry-sponsored trials to Skylight Health’s clinics in Colorado; Skylight announces the award of its first clinical trial in Colorado as part of ...
Healio

SKYLIGHT data: Fezolinetant for vasomotor symptoms appears safe, well tolerated

Please provide your email address to receive an email when new articles are posted on . All three phase 3 SKYLIGHT studies showed fezolinetant to be an acceptable treatment option for postmenopausal ...
Business Wire

Skylight Study: 85% of Americans Connect with a Higher Power; Increasing their Practice During and Since Covid Lockdowns

SALT LAKE CITY--(BUSINESS WIRE)--As the country marks the National Day of Prayer, a new study reveals insights about the habits and attitudes Americans have about prayer. The National Day of Prayer ...